Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2019

01-04-2019 | Review

Identifying adherence barriers to oral endocrine therapy among breast cancer survivors

Authors: Rutugandha Paranjpe, Grace John, Meghana Trivedi, Susan Abughosh

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Login to get access

Abstract

Purpose

Approximately 70–80% of breast cancers are hormone receptor-positive (HR+). OET, including tamoxifen and aromatase inhibitors, is considered standard adjuvant therapy for HR+ breast cancer. Despite demonstrated benefits, nearly half of patients are non-adherent and over two-thirds discontinue therapy before the recommended 5 years. Our objective was to identify and summarize literature-reported barriers associated with non-adherence/non-persistence to OET among breast cancer survivors.

Methods

A PUBMED literature search was conducted using the following terms: ‘breast cancer,’ ‘oral endocrine therapy’ or ‘Tamoxifen’ or ‘Aromatase Inhibitors,’ ‘adherence,’ or ‘barriers.’ The search was restricted to past six years. The abstracts of each result were reviewed and categorized as either patient-reported or physician-reported. All patient- and physician-reported factors that affected adherence and persistence were listed and grouped together into the three main categories: Socio-demographic and medical parameters, general psychosocial parameters, and psychosocial parameters related to OET.

Results

A total of 320 articles were identified, of which 19 met inclusion criteria. Adverse drug reactions were the most commonly reported barrier but were generally underreported among physicians. Among patient-reported barriers, common social-demographic and medical parameters were age, comorbidity, and financial status. General psychosocial variables were lack of patient–provider communication, depressive symptoms, and lack of perceived self-efficacy. Treatment toxicity was the most commonly reported psychosocial parameter related to OET.

Conclusion

The determinants of non-adherence and non-persistence are multi-dimensional and influenced by several factors. The three categories of adherence barriers should be evaluated and considered when designing future interventions to enhance OET adherence for a tailored approach.
Literature
1.
go back to reference Bowles EJ, Buist DS, Chubak J, Yu O, Johnson J, Chestnut J, Boudreau DM (2012) Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size. J Oncol Pract 8(2):113–120CrossRefPubMedPubMedCentral Bowles EJ, Buist DS, Chubak J, Yu O, Johnson J, Chestnut J, Boudreau DM (2012) Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size. J Oncol Pract 8(2):113–120CrossRefPubMedPubMedCentral
2.
go back to reference Salgado TM, Davis EJ, Farris KB, Fawaz S, Batra P, Henry NL (2017) Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer. Breast Cancer Res Treat 163(2):311–319CrossRefPubMed Salgado TM, Davis EJ, Farris KB, Fawaz S, Batra P, Henry NL (2017) Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer. Breast Cancer Res Treat 163(2):311–319CrossRefPubMed
3.
go back to reference Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137(3):829–836CrossRefPubMed Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137(3):829–836CrossRefPubMed
4.
go back to reference Milata JL, Otte JL, Carpenter JS (2018) Oral endocrine therapy nonadherence, adverse effects, decisional support, and decisional needs in women with breast cancer. Cancer Nurs 41(1):E9–E18CrossRefPubMedPubMedCentral Milata JL, Otte JL, Carpenter JS (2018) Oral endocrine therapy nonadherence, adverse effects, decisional support, and decisional needs in women with breast cancer. Cancer Nurs 41(1):E9–E18CrossRefPubMedPubMedCentral
5.
go back to reference Jinih M, Relihan N, Corrigan MA, O’Reilly S, Redmond HP (2017) Extended adjuvant endocrine therapy in breast cancer: evidence and update—a review. Breast J 23(6):694–705CrossRefPubMed Jinih M, Relihan N, Corrigan MA, O’Reilly S, Redmond HP (2017) Extended adjuvant endocrine therapy in breast cancer: evidence and update—a review. Breast J 23(6):694–705CrossRefPubMed
6.
go back to reference Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145(2):525–534CrossRefPubMed Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145(2):525–534CrossRefPubMed
7.
go back to reference Bright EE, Petrie KJ, Partridge AH, Stanton AL (2016) Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Breast Cancer Res Treat 158(2):243–251CrossRefPubMed Bright EE, Petrie KJ, Partridge AH, Stanton AL (2016) Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Breast Cancer Res Treat 158(2):243–251CrossRefPubMed
8.
go back to reference Harrow A, Dryden R, McCowan C, Radley A, Parsons M, Thompson AM, Wells M (2014) A hard pill to swallow: a qualitative study of women’s experiences of adjuvant endocrine therapy for breast cancer. BMJ Open 4(6):e005285CrossRefPubMedPubMedCentral Harrow A, Dryden R, McCowan C, Radley A, Parsons M, Thompson AM, Wells M (2014) A hard pill to swallow: a qualitative study of women’s experiences of adjuvant endocrine therapy for breast cancer. BMJ Open 4(6):e005285CrossRefPubMedPubMedCentral
9.
go back to reference Brett J, Fenlon D, Boulton M, Hulbert-Williams NJ, Walter FM, Donnelly P, Lavery B, Morgan A, Morris C, Watson E (2018) Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. Eur J Cancer Care 27(1):e12601CrossRef Brett J, Fenlon D, Boulton M, Hulbert-Williams NJ, Walter FM, Donnelly P, Lavery B, Morgan A, Morris C, Watson E (2018) Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. Eur J Cancer Care 27(1):e12601CrossRef
10.
go back to reference Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537CrossRefPubMed Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537CrossRefPubMed
11.
go back to reference Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515–1524CrossRefPubMedPubMedCentral Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515–1524CrossRefPubMedPubMedCentral
12.
go back to reference Tinari N, Fanizza C, Romero M, Gambale E, Moscetti L, Vaccaro A, Seminara P, Longo F, Gori S, Vici P et al (2015) Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey. Clin Breast Cancer 15(2):e131–e137CrossRefPubMed Tinari N, Fanizza C, Romero M, Gambale E, Moscetti L, Vaccaro A, Seminara P, Longo F, Gori S, Vici P et al (2015) Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey. Clin Breast Cancer 15(2):e131–e137CrossRefPubMed
13.
go back to reference Luschin G, Habersack M (2014) Oral information about side effects of endocrine therapy for early breast cancer patients at initial consultation and first follow-up visit: an online survey. Health Commun 29(4):421–426CrossRefPubMed Luschin G, Habersack M (2014) Oral information about side effects of endocrine therapy for early breast cancer patients at initial consultation and first follow-up visit: an online survey. Health Commun 29(4):421–426CrossRefPubMed
14.
go back to reference Milata JL, Otte JL, Carpenter JS (2016) Oral endocrine therapy nonadherence, adverse effects, decisional support, and decisional needs in women with breast cancer. Cancer Nurs 41:E9–E18CrossRef Milata JL, Otte JL, Carpenter JS (2016) Oral endocrine therapy nonadherence, adverse effects, decisional support, and decisional needs in women with breast cancer. Cancer Nurs 41:E9–E18CrossRef
15.
go back to reference Ekinci E, Nathoo S, Korattyil T, Vadhariya A, Zaghloul HA, Niravath PA, Abughosh SM, Trivedi MV (2018) Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? J Cancer Surviv 12:348–356CrossRefPubMed Ekinci E, Nathoo S, Korattyil T, Vadhariya A, Zaghloul HA, Niravath PA, Abughosh SM, Trivedi MV (2018) Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? J Cancer Surviv 12:348–356CrossRefPubMed
16.
go back to reference Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478CrossRefPubMedPubMedCentral Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478CrossRefPubMedPubMedCentral
17.
go back to reference Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD (2017) Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence 11:305–322CrossRefPubMedPubMedCentral Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD (2017) Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence 11:305–322CrossRefPubMedPubMedCentral
18.
go back to reference Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, Segui MA, Margeli M, Arcusa A, Prat A et al (2012) Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 107(8):1249–1256CrossRefPubMedPubMedCentral Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, Segui MA, Margeli M, Arcusa A, Prat A et al (2012) Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 107(8):1249–1256CrossRefPubMedPubMedCentral
19.
go back to reference Karmakar M, Pinto SL, Jordan TR, Mohamed I, Holiday-Goodman M (2017) Predicting adherence to aromatase inhibitor therapy among breast cancer survivors: an application of the protection motivation theory. Breast Cancer (Auckl) 11:1178223417694520PubMedCentral Karmakar M, Pinto SL, Jordan TR, Mohamed I, Holiday-Goodman M (2017) Predicting adherence to aromatase inhibitor therapy among breast cancer survivors: an application of the protection motivation theory. Breast Cancer (Auckl) 11:1178223417694520PubMedCentral
20.
go back to reference Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, Carrieri MP, Giorgi R (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23(4):882–890CrossRefPubMed Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, Carrieri MP, Giorgi R (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23(4):882–890CrossRefPubMed
21.
go back to reference Freedman RA, Revette AC, Hershman DL, Silva K, Sporn NJ, Gagne JJ, Kouri EM, Keating NL (2017) Understanding breast cancer knowledge and barriers to treatment adherence: a qualitative study among breast cancer survivors. Biores Open Access 6(1):159–168CrossRefPubMedPubMedCentral Freedman RA, Revette AC, Hershman DL, Silva K, Sporn NJ, Gagne JJ, Kouri EM, Keating NL (2017) Understanding breast cancer knowledge and barriers to treatment adherence: a qualitative study among breast cancer survivors. Biores Open Access 6(1):159–168CrossRefPubMedPubMedCentral
22.
go back to reference Cahir C, Dombrowski SU, Kelly CM, Kennedy MJ, Bennett K, Sharp L (2015) Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. Support Care Cancer 23(11):3115–3130CrossRefPubMed Cahir C, Dombrowski SU, Kelly CM, Kennedy MJ, Bennett K, Sharp L (2015) Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. Support Care Cancer 23(11):3115–3130CrossRefPubMed
23.
go back to reference Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii M, Chestnut J, Buist DS (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8(6):e149–e157CrossRefPubMedPubMedCentral Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii M, Chestnut J, Buist DS (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8(6):e149–e157CrossRefPubMedPubMedCentral
24.
go back to reference Gallicchio L, Calhoun C, Helzlsouer K (2017) A prospective study of aromatase inhibitor therapy initiation and self-reported side effects. Support Care Cancer 25(9):2697–2705CrossRefPubMed Gallicchio L, Calhoun C, Helzlsouer K (2017) A prospective study of aromatase inhibitor therapy initiation and self-reported side effects. Support Care Cancer 25(9):2697–2705CrossRefPubMed
25.
go back to reference Bluethmann SM, Murphy CC, Tiro JA, Mollica MA, Vernon SW, Bartholomew LK (2017) Deconstructing decisions to initiate, maintain, or discontinue adjuvant endocrine therapy in breast cancer survivors: a mixed-methods study. Oncol Nurs Forum 44(3):E101–E110CrossRefPubMedPubMedCentral Bluethmann SM, Murphy CC, Tiro JA, Mollica MA, Vernon SW, Bartholomew LK (2017) Deconstructing decisions to initiate, maintain, or discontinue adjuvant endocrine therapy in breast cancer survivors: a mixed-methods study. Oncol Nurs Forum 44(3):E101–E110CrossRefPubMedPubMedCentral
26.
go back to reference Brier MJ, Chambless DL, Gross R, Chen J, Mao JJ (2017) Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors. Cancer 123(1):169–176CrossRefPubMed Brier MJ, Chambless DL, Gross R, Chen J, Mao JJ (2017) Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors. Cancer 123(1):169–176CrossRefPubMed
27.
go back to reference Wheeler SB, Roberts MC, Bloom D, Reeder-Hayes KE, Espada M, Peppercorn J, Golin CE, Earp JA (2016) Oncology providers’ perspectives on endocrine therapy prescribing and management. Patient Prefer Adher 10:2007–2019CrossRef Wheeler SB, Roberts MC, Bloom D, Reeder-Hayes KE, Espada M, Peppercorn J, Golin CE, Earp JA (2016) Oncology providers’ perspectives on endocrine therapy prescribing and management. Patient Prefer Adher 10:2007–2019CrossRef
28.
go back to reference Samuel CA, Turner K, Donovan HAS, Beckjord E, Cardy A, Dew MA, van Londen GJ (2017) Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management. Support Care Cancer 25(12):3723–3731CrossRefPubMedPubMedCentral Samuel CA, Turner K, Donovan HAS, Beckjord E, Cardy A, Dew MA, van Londen GJ (2017) Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management. Support Care Cancer 25(12):3723–3731CrossRefPubMedPubMedCentral
29.
go back to reference Brier MJ, Chambless D, Gross R, Su HI, DeMichele A, Mao JJ (2015) Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors. Eur J Cancer 51(14):1890–1896CrossRefPubMed Brier MJ, Chambless D, Gross R, Su HI, DeMichele A, Mao JJ (2015) Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors. Eur J Cancer 51(14):1890–1896CrossRefPubMed
30.
go back to reference Lambert LK, Balneaves LG, Howard AF, Gotay CC (2018) Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat 167(3):615–633CrossRefPubMed Lambert LK, Balneaves LG, Howard AF, Gotay CC (2018) Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat 167(3):615–633CrossRefPubMed
31.
go back to reference Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S, Study I (2009) Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 200(3):238–e238CrossRef Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S, Study I (2009) Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 200(3):238–e238CrossRef
32.
go back to reference Bertelli G, Venturini M, Del Mastro L, Bergaglio M, Sismondi P, Biglia N, Venturini S, Porcile G, Pronzato P, Costantini M et al (2002) Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 13(6):883–888CrossRefPubMed Bertelli G, Venturini M, Del Mastro L, Bergaglio M, Sismondi P, Biglia N, Venturini S, Porcile G, Pronzato P, Costantini M et al (2002) Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 13(6):883–888CrossRefPubMed
33.
go back to reference Miller WR, Rollnick S (2009) Ten things that motivational interviewing is not. Behav Cogn Psychother 37(2):129–140CrossRefPubMed Miller WR, Rollnick S (2009) Ten things that motivational interviewing is not. Behav Cogn Psychother 37(2):129–140CrossRefPubMed
34.
go back to reference Velasquez MSK, Dodrill C, Kan L (2005) The transtheoretical model as a framework for developing substance abuse interventions. J Addict Nurs 16:31–40CrossRef Velasquez MSK, Dodrill C, Kan L (2005) The transtheoretical model as a framework for developing substance abuse interventions. J Addict Nurs 16:31–40CrossRef
35.
go back to reference Christie D, Channon S (2014) The potential for motivational interviewing to improve outcomes in the management of diabetes and obesity in paediatric and adult populations: a clinical review. Diabetes Obes Metab 16(5):381–387CrossRefPubMed Christie D, Channon S (2014) The potential for motivational interviewing to improve outcomes in the management of diabetes and obesity in paediatric and adult populations: a clinical review. Diabetes Obes Metab 16(5):381–387CrossRefPubMed
36.
go back to reference Abughosh S, Wang X, Serna O, Esse T, Mann A, Masilamani S, Holstad MM, Essien EJ, Fleming M (2017) A motivational interviewing intervention by pharmacy students to improve medication adherence. J Manag Care Spec Pharm 23(5):549–560PubMed Abughosh S, Wang X, Serna O, Esse T, Mann A, Masilamani S, Holstad MM, Essien EJ, Fleming M (2017) A motivational interviewing intervention by pharmacy students to improve medication adherence. J Manag Care Spec Pharm 23(5):549–560PubMed
37.
go back to reference DiIorio C, McCarty F, Resnicow K, McDonnell Holstad M, Soet J, Yeager K, Sharma SM, Morisky DE, Lundberg B (2008) Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. AIDS Care 20(3):273–283CrossRefPubMedPubMedCentral DiIorio C, McCarty F, Resnicow K, McDonnell Holstad M, Soet J, Yeager K, Sharma SM, Morisky DE, Lundberg B (2008) Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. AIDS Care 20(3):273–283CrossRefPubMedPubMedCentral
38.
go back to reference Ogedegbe G, Chaplin W, Schoenthaler A, Statman D, Berger D, Richardson T, Phillips E, Spencer J, Allegrante JP (2008) A practice-based trial of motivational interviewing and adherence in hypertensive African Americans. Am J Hypertens 21(10):1137–1143CrossRefPubMedPubMedCentral Ogedegbe G, Chaplin W, Schoenthaler A, Statman D, Berger D, Richardson T, Phillips E, Spencer J, Allegrante JP (2008) A practice-based trial of motivational interviewing and adherence in hypertensive African Americans. Am J Hypertens 21(10):1137–1143CrossRefPubMedPubMedCentral
Metadata
Title
Identifying adherence barriers to oral endocrine therapy among breast cancer survivors
Authors
Rutugandha Paranjpe
Grace John
Meghana Trivedi
Susan Abughosh
Publication date
01-04-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-05073-z

Other articles of this Issue 2/2019

Breast Cancer Research and Treatment 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine